Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease

AIMS: The metabolic pathways leading to the formation of prasugrel and clopidogrel active metabolites differ. We hypothesized that decreased CYP2C19 activity affects the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. METHODS AND RESULTS: Ninety-eight patients with cor...

Descripción completa

Detalles Bibliográficos
Autores principales: Varenhorst, Christoph, James, Stefan, Erlinge, David, Brandt, John T., Braun, Oscar Ö., Man, Michael, Siegbahn, Agneta, Walker, Joseph, Wallentin, Lars, Winters, Kenneth J., Close, Sandra L.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2009
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2709885/
https://www.ncbi.nlm.nih.gov/pubmed/19429918
http://dx.doi.org/10.1093/eurheartj/ehp157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2709885/
https://www.ncbi.nlm.nih.gov/pubmed/19429918
http://dx.doi.org/10.1093/eurheartj/ehp157

Ejemplares similares